BIONEWS
J&J's Sail deal, an option rather than a buyout, is the latest of roughly $8B in 18 month Big Pharma bets on in vivo CAR T, which engineers immune cells inside the patient instead of in a lab.
J&J's $785M option on Sail Biomedicines is the freshest data point in an 18-month, multi-billion-dollar Big Pharma convergence on a single idea: reprogramming the body's immune cells from the inside, instead of extracting them, shipping them to a factory, and reinfusing them. The approach, known as in vivo CAR-T, has drawn at least four large drugmakers willing to put roughly $8B in upfront cash on the table to see if it works in autoimmune disease, a category that has long been treated with lifelong immune suppression rather than cure.
The Sail agreement, announced Wednesday, gives J&J $465M in equity, up to $140M in near-term milestones, and an exclusive option to acquire the company for an additional $2.58B. J&J described the deal as the centerpiece of an effort to build an "immune-reset" modality that can scale beyond a single target. The lead asset, SAIL-0839, is designed to reprogram both CD4 and CD8 T cells inside the body, with stated indications including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
What separates in vivo CAR-T from the approved CAR-T drugs of the last decade is the manufacturing step. Existing therapies take a patient's T cells out, engineer them to recognize a target, grow them up, and put them back. That works, but it requires apheresis (drawing and processing the patient's blood to isolate the cells), a specialized center, weeks of waiting, and a list price that runs into the hundreds of thousands of dollars. In vivo CAR-T skips the factory. Sail's platform uses engineered circular RNA, called eRNA, packaged inside lipid nanoparticles targeted to T cells. The nanoparticles are infused; the T cells are reprogrammed in place.
Sail's preclinical case rests on two mouse models in which one or a few injections depleted B cells in lymphoid tissue. B cells are the immune-cell subset that drives many autoimmune diseases, and the company frames durable B-cell depletion as the lever for an "immune reset": a one-time or short-course treatment that removes the autoreactive cells and lets the immune system rebuild without them. Ex vivo CD19 CAR-T has already put some lupus patients into long, drug-free remission, which is why the same Big Pharma houses that watched those results are now writing checks for the in vivo version.
The check-writing has been steady. AbbVie paid $2.1B for Capstan, whose lead candidate CPTX2309 is an anti-CD19 in vivo CAR-T now in Phase 1 for SLE and RA. Bristol Myers Squibb took Orbital for $1.5B at a preclinical stage. Eli Lilly closed a $3.25B acquisition of Kelonia in April 2026. J&J itself had partnered with Kelonia before that deal. Add Sail's $785M, and the upfront-cash total on in vivo CAR-T for autoimmune disease lands in the high single-digit billions over 18 months.
The clinical evidence is thinner than the deal flow. Sail's B-cell depletion data is in mice. Capstan's CPTX2309 is in early human studies, with readouts still pending. Kelonia and Orbital are earlier still. The ex vivo CD19 CAR-T results in lupus are the cleanest signal that the underlying biology can work, but even there, durability after the engineered cells have cleared from the body is the unresolved question. The Sail agreement is an exclusive option, not an acquisition, and the option typically converts only on data good enough to justify the price.
The next test is whether SAIL-0839 can deplete B cells in patients the way it does in mice, and on what timeline. If the mouse data holds, autoimmune treatment could shift from chronic immune suppression to a finite course of infusions. The Big Pharma queue to find out now includes J&J.